Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media
Multiparametric methods for early detection of prostate cancer

Junior Clinical Cooperation Unit Multiparametric methods for early detection of prostate cancer

Dr. Magdalena Görtz

Targeted prostate cancer detection by magnetic resonance imaging/ultrasound fusion biopsy.
© dkfz.de

Our clinical cooperation unit at the DKFZ and University Hospital Heidelberg aims at developing more individualized approaches for prostate cancer diagnostics and therapy planning. Prostate cancer is characterized by a considerable heterogeneity of aggressiveness and disease progression. In case of suspicious examination findings, MRI imaging and histological securing of the prostate are indicated. However, with the current means for early detection of prostate cancer, not only aggressive but also indolent prostate cancer are diagnosed, which would not result in increased morbidity or mortality.
In our group, we prospectively and systematically compile clinical, laboratory-chemical, radiological, molecular biological and histopathological data for the development of new diagnostic strategies for prostate cancer. Integrated patient data allows to investigate new analytical methods and their prognostic significance, among others parameter extraction, deep neural networks and machine learning. There is an urgent need for new molecular markers to improve diagnostics and risk stratification of prostate cancer. Among others, we investigate predictive biomarkers in form of epigenetic modifications in the circulating cell-free DNA of liquid biopsy samples from prostate cancer patients.

An integrative early detection and risk stratification strategy that combines molecular markers with imaging has the potential to optimize non-invasive diagnostics, to develop more precise prediction models and to allow correlations with tumour aggressiveness. The aim of our clinical cooperation unit is to identify new biomarkers and diagnostic models with predictive and prognostic relevance for the presence and aggressiveness of prostate cancer. In the future, more individualized approaches for the diagnostics and therapy planning of patients with prostate cancer are to be developed.

Contact

Dr. Magdalena Görtz
Multiparametric methods for early detection of prostate cancer (E250)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 223
69120 Heidelberg
Tel: +49 6221/42-2603

Selected Publications

  • Tavakoli, A. A. et al. Measured Multipoint Ultra-High b-Value Diffusion MRI in the Assessment of MRI-Detected Prostate Lesions. Invest Radiol, doi:10.1097/RLI.0000000000000712 (2020).
  • Nientiedt, C. et al. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naive metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel. Urol Oncol 38, 637 e617-637 e627, doi:10.1016/j.urolonc.2020.03.001 (2020).
  • Görtz, M. et al. The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies. Eur Urol Focus, doi:10.1016/j.euf.2019.11.012 (2019).
  • Radtke, J. P. et al. Prediction of significant prostate cancer in biopsy-naive men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS. PLoS One 14, e0221350, doi:10.1371/journal.pone.0221350 (2019).
to top
powered by webEdition CMS